NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

$59.19 -0.69 (-1.15 %)
(As of 04/22/2018 02:25 AM ET)
Previous Close$59.19
Today's Range$58.8150 - $59.95
52-Week Range$42.88 - $64.60
Volume5.87 million shs
Average Volume6.38 million shs
Market Capitalization$104.57 billion
P/E Ratio23.68
Dividend Yield1.87%
Beta1.5

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100

Debt

Debt-to-Equity Ratio0.87%
Current Ratio2.26%
Quick Ratio1.86%

Price-To-Earnings

Trailing P/E Ratio23.68
Forward P/E Ratio20.70
P/E Growth1.77

Sales & Book Value

Annual Sales$27.39 billion
Price / Sales3.77
Cash Flow$4.7314 per share
Price / Cash12.51
Book Value$17.87 per share
Price / Book3.31

Profitability

EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins1.67%
Return on Equity14.53%
Return on Assets6.29%

Miscellaneous

Employees99,000
Outstanding Shares1,746,330,000

How to Become a New Pot Stock Millionaire

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Stockholders of record on Friday, April 13th will be given a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 annualized dividend and a dividend yield of 1.89%. The ex-dividend date of this dividend is Thursday, April 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings results on Wednesday, April, 18th. The healthcare product maker reported $0.59 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.58 by $0.01. The healthcare product maker earned $7.39 billion during the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a return on equity of 14.53% and a net margin of 1.67%. The business's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.48 earnings per share. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY18 earnings guidance on Wednesday, April, 18th. The company provided earnings per share (EPS) guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.

What price target have analysts set for ABT?

18 brokerages have issued 1 year price objectives for Abbott Laboratories' shares. Their predictions range from $45.00 to $80.00. On average, they anticipate Abbott Laboratories' share price to reach $67.00 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White, Chairman & CEO (Age 63)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
  • Mr. Brian J. Blaser, Exec. VP of Diagnostic Products (Age 53)
  • Scott M. Leinenweber, VP of Investor Relations
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)

Has Abbott Laboratories been receiving favorable news coverage?

Press coverage about ABT stock has trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.19 on Accern's scale. They also gave news articles about the healthcare product maker an impact score of 45.96 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $59.19.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $104.57 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  639 (Vote Outperform)
Underperform Votes:  486 (Vote Underperform)
Total Votes:  1,125
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abbott Laboratories (NYSE:ABT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Abbott Laboratories in the last 12 months. Their average twelve-month price target is $67.00, suggesting that the stock has a possible upside of 13.19%. The high price target for ABT is $80.00 and the low price target for ABT is $45.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.742.712.60
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $67.00$65.5556$60.00$56.5333
Price Target Upside: 13.19% upside4.30% upside1.16% upside1.37% upside

Abbott Laboratories (NYSE:ABT) Consensus Price Target History

Price Target History for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2018ArgusBoost Price TargetBuy$66.00 -> $80.00LowView Rating Details
1/30/2018CitigroupBoost Price TargetNeutral -> Neutral$59.00 -> $64.00LowView Rating Details
1/25/2018BarclaysBoost Price TargetOverweight -> Overweight$66.00 -> $70.00LowView Rating Details
1/25/2018GuggenheimReiterated RatingBuy$72.00LowView Rating Details
1/25/2018Royal Bank of CanadaReiterated RatingBuy$67.00LowView Rating Details
1/25/2018Leerink SwannReiterated RatingMarket Perform$60.00 -> $68.00LowView Rating Details
1/25/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$65.00 -> $69.00HighView Rating Details
1/25/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$67.00 -> $70.00HighView Rating Details
1/25/2018Wells FargoBoost Price TargetOutperform$66.00 -> $70.00MediumView Rating Details
1/25/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$65.00 -> $70.00MediumView Rating Details
1/25/2018Stifel NicolausBoost Price TargetBuy -> Buy$63.00 -> $71.00MediumView Rating Details
1/25/2018William BlairUpgradeMarket Perform -> OutperformMediumView Rating Details
1/24/2018Bank of AmericaBoost Price Target$60.00 -> $70.00HighView Rating Details
1/22/2018BTIG ResearchDowngradeBuy -> NeutralMediumView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$64.00LowView Rating Details
10/19/2017CowenSet Price TargetBuy$55.00 -> $68.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingBuy$65.00N/AView Rating Details
5/16/2017Goldman SachsInitiated CoverageNeutral -> Neutral$45.00LowView Rating Details
4/18/2017UBSReiterated RatingNeutral$41.00N/AView Rating Details
8/9/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper JaffrayDowngradeOverweight -> NeutralN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Abbott Laboratories (NYSE:ABT) Earnings History and Estimates Chart

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Earnings Estimates

2018 EPS Consensus Estimate: $2.83
2019 EPS Consensus Estimate: $3.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.57$0.58$0.57
Q2 20183$0.71$0.71$0.71
Q3 20183$0.73$0.75$0.74
Q4 20183$0.79$0.83$0.81
Q1 20192$0.66$0.66$0.66
Q2 20192$0.79$0.79$0.79
Q3 20192$0.82$0.82$0.82
Q4 20192$0.92$0.93$0.93

Abbott Laboratories (NYSE ABT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/18/2018$0.71N/AView Earnings Details
4/18/2018Q1 18$0.58$0.59$7.2831 billion$7.39 billionViewN/AView Earnings Details
1/24/2018Q4 2017$0.73$0.74$7.3844 billion$7.5890 billionViewListenView Earnings Details
10/18/20179/30/2017$0.65$0.66$6.7160 billion$6.8290 billionViewN/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.6273 billion$6.6370 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.1623 billion$6.3350 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
10/20/2010Q3 2010$1.04$1.05ViewN/AView Earnings Details
7/21/2010Q2 2010$1.00$1.01ViewN/AView Earnings Details
4/21/2010Q1 2010$0.80$0.81ViewN/AView Earnings Details
1/27/2010Q4 2009$1.17$1.18ViewN/AView Earnings Details
10/14/2009Q3 2009$0.90$0.92ViewN/AView Earnings Details
7/15/2009Q2 2009$0.89$0.90ViewN/AView Earnings Details
4/15/2009Q1 2009$0.70$0.73ViewN/AView Earnings Details
1/21/2009Q4 2008$1.06$1.06ViewN/AView Earnings Details
10/15/2008Q3 2008$0.77$0.79ViewN/AView Earnings Details
7/16/2008Q2 2008$0.78$0.84ViewN/AView Earnings Details
4/16/2008Q1 2008$0.63$0.63ViewN/AView Earnings Details
1/23/2008Q4 2007$0.92$0.93ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Abbott Laboratories (NYSE:ABT) Dividend Information

Abbott Laboratories pays an annual dividend of $1.12 per share, with a dividend yield of 1.89%. ABT's next quarterly dividend payment will be made on Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 6.40% each year. Abbott Laboratories pays out 44.80% of its earnings out as a dividend.
Next Dividend:5/15/2018
Annual Dividend:$1.12
Dividend Yield:1.89%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio:44.80% (Trailing 12 Months of Earnings)
39.16% (Based on This Year's Estimates)
34.67% (Based on Next Year's Estimates)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2018quarterly$0.281.85415114642828%4/12/20184/13/20185/15/2018
12/15/2017quarterly$0.281.99%1/11/20181/12/20182/15/2018
9/15/2017quarterly$0.26502.05%10/12/201710/13/201711/15/2017
6/9/2017quarterly$0.26502.25%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.26502.36%4/11/20174/14/20175/15/2017
12/9/2016quarterly$0.26502.7%1/11/20171/13/20172/15/2017
9/15/2016quarterly$0.262.48%10/12/201610/14/201611/15/2016
6/10/2016quarterly$0.262.75%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.262.66%4/13/20164/15/20165/16/2016
12/11/2015quarterly$0.262.32%1/13/20161/15/20162/16/2016
9/17/2015quarterly$0.242.22%10/13/201510/15/201511/15/2015
6/12/2015quarterly$0.242%7/13/20157/15/20158/15/2015
2/20/2015quarterly$0.242.03%4/13/20154/15/20155/15/2015
12/12/2014quarterly$0.242.21%1/13/20151/15/20152/13/2015
9/11/2014quarterly$0.222.07%10/10/201410/15/201411/15/2014
6/13/2014quarterly$0.222.21%7/11/20147/15/20148/15/2014
2/21/2014quarterly$0.222.26%4/11/20144/15/20145/15/2014
10/16/2013quarterly$0.222.37%1/13/20141/15/20142/15/2014
9/12/2013quarterly$0.141.61%10/10/201310/15/201311/15/2013
6/14/2013quarterly$0.141.52%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.141.61%4/11/20134/15/20135/15/2013
12/14/2012quarterly$0.140.86%1/11/20131/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 72.34%
Insider Trading History for Abbott Laboratories (NYSE:ABT)
Insider Trading History for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Roger BirdInsiderSell8,262$62.75$518,440.5058,574View SEC Filing  
3/7/2018Jared WatkinInsiderSell3,000$61.19$183,570.0068,215View SEC Filing  
3/5/2018Sharon J BrackenSVPSell2,100$60.27$126,567.0044,790View SEC Filing  
3/1/2018Jared WatkinSVPSell996$58.87$58,634.5269,511View SEC Filing  
3/1/2018Sharon J BrackenInsiderSell1,053$58.93$62,053.29View SEC Filing  
3/1/2018Stephen R FussellEVPSell11,106$60.13$667,803.78172,158View SEC Filing  
2/27/2018Daniel J StarksDirectorBuy40,037$60.67$2,429,044.796,943,348View SEC Filing  
2/20/2018Jared WatkinSVPSell297$59.29$17,609.1374,357View SEC Filing  
2/20/2018Stephen R FussellInsiderSell56,401$59.61$3,362,063.61184,884View SEC Filing  
1/31/2018Brian J BlaserInsiderSell27,733$62.26$1,726,656.58156,587View SEC Filing  
1/30/2018Stephen R FussellEVPSell13,313$62.84$836,588.92152,343View SEC Filing  
12/14/2017Daniel Gesua Sive SalvadoriInsiderSell28,319$54.92$1,555,279.48102,117View SEC Filing  
12/6/2017Miles D WhiteChairmanSell276,886$54.41$15,065,367.263,677,913View SEC Filing  
11/30/2017Sharon J BrackenInsiderSell2,188$56.12$122,790.5625,618View SEC Filing  
11/22/2017Alejandro D WellischInsiderSell2,153$55.86$120,266.5810,256View SEC Filing  
11/17/2017Brian J BlaserInsiderSell23,866$55.55$1,325,756.30146,387View SEC Filing  
11/14/2017Daniel Gesua Sive SalvadoriInsiderSell71,157$55.00$3,913,635.00144,955View SEC Filing  
10/23/2017Daniel Gesua Sive SalvadoriEVPSell96,603$56.21$5,430,054.63142,082View SEC Filing  
9/26/2017Daniel Gesua Sive SalvadoriInsiderSell62,460$52.95$3,307,257.00113,426View SEC Filing  
9/22/2017Jaime ContrerasInsiderSell52,700$51.97$2,738,819.0058,739View SEC Filing  
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00221,488View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.0028,806View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00143,154View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00105,479View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.4447,090View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00221,488View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.0051,313View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.0026,224View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00117,579View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.4463,910View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.6258,471View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00100,189View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00129,782View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.7551,532View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.202,802,558View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.0020,143View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.6559,791View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00196,467View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.0081,811View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.462,010,517View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00111,819View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.0091,857View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.7647,114View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.8550,182View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.4347,435View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.3647,667View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.8052,250View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.1148,364View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.6862,495View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.9086,352View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.8650,515View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.2334,941View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.001,394,153View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16130,601View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.3495,131View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.3947,525View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.6162,926View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30102,421View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.3040,487View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.3030,901View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94101,169View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abbott Laboratories (NYSE ABT) News Headlines

Source:
DateHeadline
Abbott Laboratories (ABT) Coverage Initiated by Analysts at BTIG ResearchAbbott Laboratories (ABT) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - April 20 at 6:24 PM
Top Analyst Reports for Goldman Sachs, Abbott & AltriaTop Analyst Reports for Goldman Sachs, Abbott & Altria
finance.yahoo.com - April 20 at 5:20 PM
Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
finance.yahoo.com - April 20 at 5:20 PM
Abbott Laboratories (ABT) Lifted to Buy at Zacks Investment ResearchAbbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:54 AM
Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% SensitiveEarnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive
www.nasdaq.com - April 20 at 8:33 AM
FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)
www.americanbankingnews.com - April 20 at 8:32 AM
Abbott Laboratories (ABT) to Post Q3 2018 Earnings of $0.73 Per Share, Leerink Swann ForecastsAbbott Laboratories (ABT) to Post Q3 2018 Earnings of $0.73 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 20 at 8:08 AM
Jefferies Group Weighs in on Abbott Laboratories Q3 2018 Earnings (ABT)Jefferies Group Weighs in on Abbott Laboratories' Q3 2018 Earnings (ABT)
www.americanbankingnews.com - April 20 at 8:08 AM
Abbott Laboratories (ABT) Earns Hold Rating from BMO Capital MarketsAbbott Laboratories (ABT) Earns Hold Rating from BMO Capital Markets
www.americanbankingnews.com - April 19 at 5:50 PM
Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart ValvesAortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
finance.yahoo.com - April 19 at 5:32 PM
Abbott Laboratories (ABT) Q1 2018 Earnings Conference Call TranscriptAbbott Laboratories (ABT) Q1 2018 Earnings Conference Call Transcript
www.msn.com - April 19 at 8:52 AM
Abbott (ABT) Q1 Earnings & Revenues Top, 18 View RetainedAbbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
www.zacks.com - April 18 at 5:12 PM
Abbott Laboratories (ABT) CEO Miles White on Q1 2018 Results - Earnings Call TranscriptAbbott Laboratories' (ABT) CEO Miles White on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 18 at 5:12 PM
Abbott CEO: New Glucose Devices U.S. Launch Has Gone Exceptionally WellAbbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'
www.thestreet.com - April 18 at 5:12 PM
Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm?Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - April 18 at 5:12 PM
Abbott Shares Topple After Pharma Unit Struggles In First QuarterAbbott Shares Topple After Pharma Unit Struggles In First Quarter
finance.yahoo.com - April 18 at 5:12 PM
Abbott Laboratories Stock Slips Despite Earnings BeatAbbott Laboratories Stock Slips Despite Earnings Beat
investorplace.com - April 18 at 1:13 PM
Earnings In Focus: Apr. 18 (ABT, PIR, STLD)Earnings In Focus: Apr. 18 (ABT, PIR, STLD)
www.finanznachrichten.de - April 18 at 8:53 AM
Abbott Laboratories Q1 adjusted earnings Beat EstimatesAbbott Laboratories Q1 adjusted earnings Beat Estimates
www.nasdaq.com - April 18 at 8:53 AM
Abbott Labs quarterly revenue rises 16.7 percentAbbott Labs' quarterly revenue rises 16.7 percent
www.reuters.com - April 18 at 8:53 AM
Abbott (ABT) Beats on Earnings and Revenues in Q1Abbott (ABT) Beats on Earnings and Revenues in Q1
www.zacks.com - April 18 at 8:53 AM
Abbott: 1Q Earnings SnapshotAbbott: 1Q Earnings Snapshot
finance.yahoo.com - April 18 at 8:53 AM
Abbott Reports First-Quarter 2018 ResultsAbbott Reports First-Quarter 2018 Results
finance.yahoo.com - April 18 at 8:53 AM
Abbotts quarterly profit, sales beat Street estimatesAbbott's quarterly profit, sales beat Street estimates
finance.yahoo.com - April 18 at 8:53 AM
Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year GuidanceAbbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance
finance.yahoo.com - April 18 at 8:53 AM
Abbott Labs beats profit and sales expectations, shares slipAbbott Labs beats profit and sales expectations, shares slip
finance.yahoo.com - April 18 at 8:53 AM
Abbott Laboratories Earnings Top Views On Solid Organic SalesAbbott Laboratories Earnings Top Views On Solid Organic Sales
finance.yahoo.com - April 18 at 8:53 AM
Abbott Laboratories (ABT) Issues Q2 Earnings GuidanceAbbott Laboratories (ABT) Issues Q2 Earnings Guidance
www.americanbankingnews.com - April 18 at 8:50 AM
Abbott Laboratories (ABT) Issues FY18 Earnings GuidanceAbbott Laboratories (ABT) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 18 at 8:50 AM
Abbott Laboratories (ABT) Posts Quarterly  Earnings Results, Beats Estimates By $0.01 EPSAbbott Laboratories (ABT) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - April 18 at 8:50 AM
 Analysts Anticipate Abbott Laboratories (ABT) Will Post Quarterly Sales of $7.26 Billion Analysts Anticipate Abbott Laboratories (ABT) Will Post Quarterly Sales of $7.26 Billion
www.americanbankingnews.com - April 18 at 3:02 AM
Abbotts New Ensure® Max Protein Helps Americans Go for Their #HealthGoalsAbbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals
finance.yahoo.com - April 17 at 5:23 PM
Glucose Monitoring Device in Focus as Abbott Preps to Unveil EarningsGlucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings
finance.yahoo.com - April 17 at 5:23 PM
3 Stocks to Buy Ahead of Earnings3 Stocks to Buy Ahead of Earnings
finance.yahoo.com - April 16 at 5:22 PM
Is Abbott Laboratories (NYSE:ABT) Worth $58.49 Based On Intrinsic Value?Is Abbott Laboratories (NYSE:ABT) Worth $58.49 Based On Intrinsic Value?
finance.yahoo.com - April 16 at 5:22 PM
Zacks: Analysts Expect Abbott Laboratories (ABT) to Announce $0.58 Earnings Per ShareZacks: Analysts Expect Abbott Laboratories (ABT) to Announce $0.58 Earnings Per Share
www.americanbankingnews.com - April 16 at 1:08 PM
BidaskClub Lowers Abbott Laboratories (ABT) to BuyBidaskClub Lowers Abbott Laboratories (ABT) to Buy
www.americanbankingnews.com - April 15 at 12:36 AM
Abbott Laboratories (ABT) Given "Buy" Rating at Jefferies GroupAbbott Laboratories (ABT) Given "Buy" Rating at Jefferies Group
www.americanbankingnews.com - April 13 at 11:43 PM
Can Solid Medical Devices Drive Abbotts (ABT) Q1 Earnings?Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 13 at 5:19 PM
Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 13 at 5:19 PM
Can Solid EPD Business Drive Abbotts (ABT) Q1 Earnings?Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
www.zacks.com - April 12 at 9:04 AM
Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery DiseaseAbbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease
finance.yahoo.com - April 11 at 5:13 PM
Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 11 at 5:13 PM
Can Steady Overall Growth Drive Abbotts (ABT) Q1 Earnings?Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
www.zacks.com - April 11 at 8:50 AM
Abbott Laboratories (ABT) to Release Quarterly Earnings on WednesdayAbbott Laboratories (ABT) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 11 at 1:34 AM
Abbott Laboratories Stock Performance in 1Q18Abbott Laboratories Stock Performance in 1Q18
finance.yahoo.com - April 10 at 5:17 PM
New Trial Data Show Improved Clinical Outcomes with HeartMate3New Trial Data Show Improved Clinical Outcomes with HeartMate3
finance.yahoo.com - April 9 at 5:18 PM
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align Technology, and AvingerQuotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align Technology, and Avinger
www.bizjournals.com - April 9 at 9:04 AM
Abbott Laboratories (ABT) Buy Rating Reiterated at Royal Bank of CanadaAbbott Laboratories' (ABT) Buy Rating Reiterated at Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM
Abbott Laboratories (ABT) Raised to Buy at Zacks Investment ResearchAbbott Laboratories (ABT) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:11 AM

SEC Filings

Abbott Laboratories (NYSE:ABT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abbott Laboratories (NYSE ABT) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.